Amneal Pharmaceuticals (AMRX) Common Equity (2017 - 2026)

Amneal Pharmaceuticals has reported Common Equity for 10 years, with the latest figure at $33.0 million in Q2 2026.

• On a quarterly basis, Common Equity rose 129.35% year-over-year to $33.0 million in Q2 2026; TTM through Jun 2026 was $33.0 million, a 129.35% increase from a year earlier, with the FY2025 full-year figure at -$71.3 million, up 34.87% from the prior year.
• Common Equity was $33.0 million for Q2 2026 at Amneal Pharmaceuticals, up from -$46.0 million in the prior quarter.
• The five-year high for Common Equity was $407.4 million in Q1 2022, with the low at -$132.0 million in Q1 2025.
• Average Common Equity over 5 years is $36.4 million, with a median of -$13.0 million recorded in 2023.
• The sharpest annual moves came in 2024 and 2026: Common Equity slumped 647.26% in 2024, then jumped 129.35% in 2026.
• Over 5 years, Common Equity stood at $184.0 million in 2022, then plunged by 89.12% to $20.0 million in 2023, then plunged by 647.26% to -$109.5 million in 2024, then surged by 34.87% to -$71.3 million in 2025, then soared by 146.3% to $33.0 million in 2026.
• The last three Common Equity figures came in at $33.0 million (Q2 2026), -$46.0 million (Q1 2026), and -$71.3 million (Q4 2025), per Business Quant data.